english.prescrire.org > Prescrire International > N°184 - July 2017

n°184

July 2017

Issue Contents
Editorial

Free  The sorcerer's apprentice

p.171

Marketing Authorisations

Safinamide (Xadago°) and Parkinson's disease with motor fluctuations

p.173-176
Just another MAO-B inhibitor with no proven advantages

Pertuzumab (Perjeta°) before breast cancer surgery

p.176-177
Co-administered with trastuzumab: no benefit but more adverse effects

Pertuzumab (Perjeta°) and metastatic breast cancer

p.178-179
Longer survival confirmed, but cardiac risks to be monitored

INN Common stem: -ifene, -mifene, -oxifene

p.179

Equine oestrogens + bazedoxifene (Duavive°) and menopause

p.180-182
Inadequately evaluated harms

Adverse Effects

Varenicline and neuropsychiatric disorders: caution, despite the Eagles trial abstract

p.183-185

Aliskiren: withdrawal of reimbursement in sight

p.185

Benfluorex: aortic and mitral stenosis as well

p.185

Ambroxol mouth spray: a drug to avoid

p.186

Rivaroxaban: agranulocytosis and Stevens-Johnson syndrome

p.186

Free  Temsirolimus: risk of myocardial infarction

p.187

Free  Pholcodine: anaphylactic reactions to neuro­muscular blockers

p.187

Reviews

Graves' disease during pregnancy

p.188-192
Treatment is problematic

Fetal risks associated with Graves' disease during pregnancy

p.190

Other thyroid disorders during pregnancy

p.191

Radioactive iodine: dangerous for the fetus

p.192

Outlook

Market withdrawal due to adverse effects: frequent but often belated

p.193-195

Drugs with fatal adverse effects: left on the market too long

p.195

Masthead

Free  Masthead

p.170

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe